Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Bioengineered. 2021 Dec;12(1):914-926. doi: 10.1080/21655979.2021.1896202.
This study aimed to utilize cholesterol conjugation of 5-fluorouracil (5-FUC) and liposomal formulas to enhance the partitioning of 5-FU into low density lipoprotein (LDL) to target hepatocellular carcinoma (HCC). Thus, 5-FU and 5-FUCwere loaded into liposomes. Later, the direct loading and transfer of 5-FU, and 5-FUC from liposomes into LDL were attained. The preparations were characterized in terms of particle size, zeta potential, morphology, entrapment efficiency, and cytotoxicity using the HepG2 cell line. Moreover, the drug deposition into the LDL and liver tissues was investigated. The present results revealed that liposomal preparations have a nanosize range (155 - 194 nm), negative zeta potential (- 0.82 to - 16 mV), entrapment efficiency of 69% for 5-FU, and 66% for 5-FUC. Moreover, LDL particles have a nanosize range (28-49 nm), negative zeta potential (- 17 to -27 mV), and the entrapment efficiency is 11% for 5-FU and 85% for 5-FUC. Furthermore, 5-FUC loaded liposomes displayed a sustained release profile (57%) at 24 h compared to fast release (92%) of 5-FU loaded liposomes. 5-FUC and liposomal formulas enhanced the transfer of 5-FUC into LDL compared to 5-FU. 5-FUC loaded liposomes and LDL have greater cytotoxicity against HepG2 cell lines compared to 5-FU and 5-FUC solutions. Moreover, the deposition of 5-FUC in LDL (26.87ng/mg) and liver tissues (534 ng/gm tissue) was significantly increased 5-FUC liposomes compared to 5-FU (11.7 ng/g tissue) liposomal formulation. In conclusion, 5-FUC is a promising strategy for hepatic targeting of 5-FU through LDL-mediated gateway.
本研究旨在利用 5-氟尿嘧啶(5-FU)的胆固醇缀合和脂质体配方将 5-FU 分配到低密度脂蛋白(LDL)中,以靶向肝细胞癌(HCC)。因此,将 5-FU 和 5-FUC 载入脂质体。随后,直接载入并将 5-FU 和 5-FUC 从脂质体转移到 LDL 中。使用 HepG2 细胞系,根据粒径、zeta 电位、形态、包封效率和细胞毒性对制剂进行了表征。此外,还研究了药物在 LDL 和肝组织中的沉积。结果表明,脂质体制剂的纳米尺寸范围为(155-194nm),zeta 电位为负(-0.82 至-16mV),5-FU 的包封效率为 69%,5-FUC 的包封效率为 66%。此外,LDL 颗粒的纳米尺寸范围为(28-49nm),zeta 电位为负(-17 至-27mV),5-FU 的包封效率为 11%,5-FUC 的包封效率为 85%。此外,与 5-FU 载脂质体快速释放(92%)相比,5-FUC 载脂质体在 24 小时时显示出持续释放(57%)的特征。与 5-FU 相比,5-FUC 载脂质体和脂质体配方增强了 5-FUC 向 LDL 的转移。与 5-FU 和 5-FUC 溶液相比,5-FUC 载脂质体和 LDL 对 HepG2 细胞系具有更高的细胞毒性。此外,与 5-FU 载脂质体(11.7ng/g 组织)相比,5-FUC 载脂质体在 LDL(26.87ng/mg)和肝组织(534ng/gm 组织)中的沉积显著增加。总之,通过 LDL 介导的途径,5-FUC 是将 5-FU 靶向肝脏的一种很有前途的策略。